This archive contains the following articles listed by volume, issue and page number:
 |
|
|
Volume 17, 2013 Articles |
Title (Click for Details) |
Vol/Issue |
Page |
PreScription: How Many Pharmacies Compound and What Do They Compound? |
Vol. 17 No. 1 |
4 |
PreScription: Looking for Solutions |
Vol. 17 No. 1 |
4 |
Pediatric Health Care: An Introduction |
Vol. 17 No. 1 |
6 |
Compounding Slow-release Capsules: A Comprehensive Review and an Excel Spreadsheet for Faster Calculation of Excipients |
Vol. 17 No. 1 |
10 |
Treatment of Canine Pulmonary Hypertension: Is Tadalafil an Appropriate Alternative to Sildenafil? |
Vol. 17 No. 1 |
24 |
Treatment Options for Male Hypogonadism |
Vol. 17 No. 1 |
28 |
Adrenal Fatigue |
Vol. 17 No. 1 |
39 |
International Academy of Compounding Pharmacists' Recommendations for State-based Legislative and Regulatory Initiatives |
Vol. 17 No. 1 |
48 |
Quality Control: Analytical Methods: Calibration of Equipment and Calibration Curves |
Vol. 17 No. 1 |
50 |
Basics of Compounding: Repackaging, Part 1 |
Vol. 17 No. 1 |
54 |
Calculations |
Vol. 17 No. 1 |
62 |
Desmopressin 4-mcg/mL Injection |
Vol. 17 No. 1 |
64 |
Dobutamine 10-mg/mL Injection |
Vol. 17 No. 1 |
65 |
Granisetron 1-mg/mL Injection |
Vol. 17 No. 1 |
66 |
Ibuprofen 10-mg/mL Injection |
Vol. 17 No. 1 |
67 |
Mepivacaine Hydrochloride 1% Injection |
Vol. 17 No. 1 |
68 |
Milrinone 0.2-mg/mL Injection |
Vol. 17 No. 1 |
69 |
Neostigmine Methylsulfate 0.5-mg/mL Injection |
Vol. 17 No. 1 |
70 |
Nicardipine Hydrochloride Injection |
Vol. 17 No. 1 |
71 |
Octreotide 50-mcg/mL Injection |
Vol. 17 No. 1 |
72 |
Testosterone Cypionate 100-mg/mL Injection |
Vol. 17 No. 1 |
73 |
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women |
Vol. 17 No. 1 |
74 |
Errata |
Vol. 17 No. 1 |
86 |
PostScription: GMPs and GCPs: A Topical Comparison |
Vol. 17 No. 1 |
87 |
PreScription: Pharmacy Committees |
Vol. 17 No. 2 |
92 |
Sterilization of Compounded Parenteral Products: Verification of Autoclaves |
Vol. 17 No. 2 |
94 |
Intravenous Needle-free Injection Devices: New Information for Compounding Pharmacists |
Vol. 17 No. 2 |
100 |
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities |
Vol. 17 No. 2 |
113 |
Compounding in Ukraine |
Vol. 17 No. 2 |
124 |
International Academy of Compounding Pharmacists Legislative/Regulatory Update |
Vol. 17 No. 2 |
128 |
Quality Control Analytical Methods: Strategies to Ensure a Robust Quality-control Microbiology Program |
Vol. 17 No. 2 |
130 |
Basics of Compounding: Repackaging, Part 2 |
Vol. 17 No. 2 |
136 |
Calculations |
Vol. 17 No. 2 |
142 |
Adenosine 3-mg/mL Injection |
Vol. 17 No. 2 |
144 |
Alcohol Dehydrated Injection |
Vol. 17 No. 2 |
145 |
Betahistine 16-mg Capsules |
Vol. 17 No. 2 |
146 |
Ciprofloxacin 10-mg/mL Intravenous Injection Concentrate |
Vol. 17 No. 2 |
147 |
Cyanocobalamin 1000-mcg/mL Injection |
Vol. 17 No. 2 |
148 |
Dexrazoxane 1-mg/mL Injection |
Vol. 17 No. 2 |
149 |
Meropenem 50-mg/mL Injection |
Vol. 17 No. 2 |
150 |
Paclitaxel 6-mg/mL Injection |
Vol. 17 No. 2 |
151 |
Thiotepa 15-mg/mL Injection |
Vol. 17 No. 2 |
152 |
Verapamil Hydrochloride 2.5-mg/mL Injection |
Vol. 17 No. 2 |
153 |
Compounding Practices and Beliefs of Arizona Pharmacists |
Vol. 17 No. 2 |
154 |
Stability of Rifampin in SyrSpend SF |
Vol. 17 No. 2 |
162 |
Stability of Minoxidil in Espumil Foam Base |
Vol. 17 No. 2 |
165 |
Establishing Benchmark Rates of Microbial and Bacterial Endotoxin Contamination for Radiopharmaceuticals Compounded in Commerical Nuclear Pharmacy Settings |
Vol. 17 No. 2 |
168 |
PreScription: Compounding for Drug Shortages |
Vol. 17 No. 3 |
180 |
Complying with Occupational Safety and Health Administration Regulations: A Guide for Compounding Pharmacists |
Vol. 17 No. 3 |
182 |
Decontamination Technology: The Missing Element |
Vol. 17 No. 3 |
193 |
Optimizing Third-party Reimbursement for Compounded Medications |
Vol. 17 No. 3 |
201 |
International Academy of Compounding Pharmacists' Legislative/Regulatory Update |
Vol. 17 No. 3 |
206 |
Quality Control Analytical Methods: A Summarized Discussion of Current Good Manufacturing Practice Regulations |
Vol. 17 No. 3 |
210 |
Basics of Compounding: Potency and Stability Testing |
Vol. 17 No. 3 |
220 |
Calculations |
Vol. 17 No. 3 |
226 |
Buffered Aspirin Capsules |
Vol. 17 No. 3 |
228 |
Calcium Acetate 667-mg Capsules |
Vol. 17 No. 3 |
229 |
Estradiol 0.5-mg, 1-mg, or 2-mg Capsules |
Vol. 17 No. 3 |
230 |
Ethambutol 400-mg Capsules |
Vol. 17 No. 3 |
231 |
Isoniazid 300-mg Capsules |
Vol. 17 No. 3 |
232 |
Labetalol 50-mg Capsules |
Vol. 17 No. 3 |
233 |
Mercaptopurine 75-mg Capsules |
Vol. 17 No. 3 |
234 |
Naltrexone Hydrochloride 50-mg Capsules |
Vol. 17 No. 3 |
235 |
Prednisone 10-mg Capsules |
Vol. 17 No. 3 |
236 |
Reserpine 0.5-mg Capsules |
Vol. 17 No. 3 |
237 |
Assessing the Stability of Common Radiopharmaceuticals Compounded and Utilized Outside Package Insert Guidelines |
Vol. 17 No. 3 |
238 |
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel |
Vol. 17 No. 3 |
247 |
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline |
Vol. 17 No. 3 |
254 |
PostScription: The Pharmacist's Role in the Treatment of Cancer: A Personal Plea and Testimonial |
Vol. 17 No. 3 |
262 |
Prescription: International Journal of Pharmaceutical Compounding and MEDLINE Update |
Vol. 17 No. 4 |
268 |
Jet Injection Devices for the Needle-free Administration of Compounds, Vaccines, and Other Agents |
Vol. 17 No. 4 |
270 |
United States Pharmacopeia Chapter <797> Timeline: 1989 to 2013 |
Vol. 17 No. 4 |
283 |
Pharmacists' Liability: What My Pharmacy Law Professor Did Not Cover |
Vol. 17 No. 4 |
290 |
Types of Pharmacy/Pharmacists |
Vol. 17 No. 4 |
294 |
International Academy of Compounding Pharmacists Legislative/Regulatory Update |
Vol. 17 No. 4 |
302 |
Quality Control Analytical Methods: End-preparation Assessments and Tests for Compounded Sterile Preparations |
Vol. 17 No. 4 |
307 |
Basics of Compounding: Foam Dosage Forms |
Vol. 17 No. 4 |
312 |
Calculations |
Vol. 17 No. 4 |
324 |
Acyclovir 20-mg/mL Oral Suspension |
Vol. 17 No. 4 |
326 |
Acyclovir 200-mg Capsules |
Vol. 17 No. 4 |
327 |
Allopurinol Sodium 4-mg/mL Injection |
Vol. 17 No. 4 |
328 |
Amikacin Sulfate 250-mg/mL Injection |
Vol. 17 No. 4 |
329 |
Dacarbazine 200-mg/mL Injection |
Vol. 17 No. 4 |
330 |
Ketamine 50-mg/mL Injection |
Vol. 17 No. 4 |
331 |
Methohexital Sodium 500-mg/mL Injection |
Vol. 17 No. 4 |
332 |
Metoprolol Tartrate 1-mg/mL Injection |
Vol. 17 No. 4 |
333 |
Rifampin 300-mg and Isoniazid 150-mg Capsules |
Vol. 17 No. 4 |
334 |
Succinylcholine Chloride 50-mg/mL Injection |
Vol. 17 No. 4 |
335 |
Stability of Captopril in SyrSPend SF |
Vol. 17 No. 4 |
336 |
Patient-centered Care as Value-added Service by Compounding Pharmacists |
Vol. 17 No. 4 |
339 |
Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry |
Vol. 17 No. 4 |
344 |
Physical Stability of Coconut Oil Lotions Formulated Using a Hydrophile-lipophile System of Various Emulsifier Pairs |
Vol. 17 No. 4 |
347 |
PostScription: Traditional vs Nontraditional Pharmacy |
Vol. 17 No. 4 |
351 |
PreScription: GMPs vs. GCPs: Manufacturing and Compounding Definitions |
Vol. 17 No. 5 |
356 |
Compounding Pharmacies: Before and After an Inspection |
Vol. 17 No. 5 |
358 |
Preventing Medication Errors with Nimodipine by Compounding Proper Dosage Forms |
Vol. 17 No. 5 |
364 |
Chemical Penetration Enhancers |
Vol. 17 No. 5 |
370 |
2013 State Compounding Legislation Tracker Updated: August 12, 2013 |
Vol. 17 No. 5 |
375 |
Use of Topical Metronidazole in the Treatment of Anorectal Crohn's Disease |
Vol. 17 No. 5 |
380 |
Methocarbamol Suspension for the Treatment of Rhabdomyolysis in Equines |
Vol. 17 No. 5 |
384 |
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 1 |
Vol. 17 No. 5 |
388 |
Quality Control Analytic Methods: Quality Planning, Part 1: A Holistic and Practical Approach |
Vol. 17 No. 5 |
393 |
Basics of Compounding: Basics of Compounding with Tars |
Vol. 17 No. 5 |
400 |
Calculations |
Vol. 17 No. 5 |
412 |
Acyclovir 50-mg/mL Injection |
Vol. 17 No. 5 |
414 |
Aminocaproic Acid 250-mg/mL Injection |
Vol. 17 No. 5 |
415 |
Clindamycin 150-mg/mL Injection |
Vol. 17 No. 5 |
416 |
Fluorouracil 50-mg/mL Injection |
Vol. 17 No. 5 |
417 |
Hydroxyzine Hydrochloride 25-mg/mL Injection |
Vol. 17 No. 5 |
418 |
Indomethacin 1-mg/mL Injection |
Vol. 17 No. 5 |
419 |
Mesna 100-mg/mL Injection |
Vol. 17 No. 5 |
420 |
Methotrexate 25-mg/mL Injection |
Vol. 17 No. 5 |
421 |
Phenylephrine Hydrochloride 10-mg/mL Injection |
Vol. 17 No. 5 |
422 |
Terbutaline Sulfate 1-mg/mL Injection |
Vol. 17 No. 5 |
423 |
In Vitro Evaluation of Extemporaneously Compounded Immediate-release Capsules with Premixed Excipients, Based on the Biopharmaceutics Classification System (BCS) of the Drugs |
Vol. 17 No. 5 |
424 |
Pattern of Extemporaneous Prescriptions and Preparations in a Tertiary Health Institution: A Five-year Assessment |
Vol. 17 No. 5 |
432 |
Compatibility of Amiodarone Hydrochloride with Vasopressin During Simulated Y-site Administration |
Vol. 17 No. 5 |
436 |
PostScription: GMPs vs. GCPs: United States Pharmacopeia General Chapters |
Vol. 17 No. 5 |
439 |
PreScription: Two Milestones for the International Journal of Pharmaceutical Compounding |
Vol. 17 No. 6 |
444 |
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 |
Vol. 17 No. 6 |
446 |
Clinical Utility of Pharmacogenetic Testing in Compounding Pharmacy |
Vol. 17 No. 6 |
452 |
Considerations for Pharmacists Working in Major Disaster Areas |
Vol. 17 No. 6 |
459 |
Improving the Review of Standard Operating Procedures: A Novel Electronic System for Compounding Pharmacies |
Vol. 17 No. 6 |
465 |
Physicians, Pharmacists, and the Importance of Quality Pharmacy Compounding |
Vol. 17 No. 6 |
477 |
HR 3204 -- The Drug Quality and Security Act: What Does It Say? What Does It Mean? What Happens Now? |
Vol. 17 No. 6 |
480 |
Marketing During the Holidays |
Vol. 17 No. 6 |
482 |
Quality Control Analytical Methods: A Growing Codependency: Compounding Pharmacy and Safety |
Vol. 17 No. 6 |
485 |
Basics of Compounding: Basics of Compounding with Balsams |
Vol. 17 No. 6 |
490 |
Calculations |
Vol. 17 No. 6 |
496 |
Benztropine Mesylate 1-mg/mL Injection |
Vol. 17 No. 6 |
498 |
Cefazolin 250-mg/mL Injection |
Vol. 17 No. 6 |
499 |
Ciprofloxacin 250-mg Capsules |
Vol. 17 No. 6 |
500 |
Cortisone Acetate 25-mg Capsules |
Vol. 17 No. 6 |
501 |
Cyclopentolate Hydrochloride 0.2% and Phenylephrine Hydrochloride 1% Ophthalmic Solution |
Vol. 17 No. 6 |
502 |
Dihydroergotamine Mesylate 1-mg/mL Injection |
Vol. 17 No. 6 |
503 |
Hydrocortisone 50-mg/mL Injection (as the Sodium Succinate) |
Vol. 17 No. 6 |
504 |
Levothyroxine Sodium 100-mcg Capsules |
Vol. 17 No. 6 |
505 |
Metyrosine 250-mg Capsules |
Vol. 17 No. 6 |
506 |
Phenytoin Sodium 50-mg/mL Injection |
Vol. 17 No. 6 |
507 |
Stability of Non-aqueous Topical Tetracaine and Clotrimazole Solutions in Polypropylene Droptainer Bottles |
Vol. 17 No. 6 |
508 |
Comparing Suppository Mold Variability Which Can Lead to Dosage Errors for Suppositories Prepared with the Same or Different Molds |
Vol. 17 No. 6 |
512 |
Stability of Nitroglyercin 100 mcg/mL Stored in Polypropylene Syringes |
Vol. 17 No. 6 |
515 |
Ex Vivo Percutaneous Absorption of Ketamine, Bupivacaine, Diclofenac, Gabapentin, Orphenadrine, and Pentoxyifylline: Comparison of Versatile Cream vs. Reference Cream |
Vol. 17 No. 6 |
520 |
PostScription: Augmented Reality for Readers and Authors |
Vol. 17 No. 6 |
526 |